Business Context and Reporting Period
This Form 6-K filing by NovaBridge Biosciences (formerly I-MAB) covers the month of October 2025. The report details the formal completion of a corporate name change approved by shareholders on October 24, 2025, and filed with the Cayman Islands Registry of Companies on October 27, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate disclosure regarding a name change and does not contain financial statements or performance data.
Material Changes
- Corporate Identity: The Company officially changed its name from "I-MAB" to "NovaBridge Biosciences."
- Trading Symbol: American Depositary Shares (ADSs) commenced trading on the Nasdaq Global Market under the new ticker symbol "NBP" on October 30, 2025.
- Strategic Positioning: The new brand and logo reflect a strategic transformation to a global biotech platform.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary on future performance. It notes that the CUSIP number for the ADSs remains unchanged and no further action is required by shareholders. The document incorporates by reference into various Registration Statements (Form F-3 and Form S-8) but does not list specific risks or contingencies within this text.
Key Facts for Investor Verification
- Verify the new ticker symbol "NBP" on the Nasdaq Global Market effective October 30, 2025.
- Confirm that the CUSIP number remains unchanged despite the name and ticker transition.
- Review the attached press release (Exhibit 99.1) for details on the strategic transformation to a global biotech platform.
- Check subsequent filings for the first financial report under the new corporate name.